Payment overview · 2025
General Payments
$424.29
24 reported records · 12 companies
Healthcare provider profile · identity verified
Douglas L Davis, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · KNOXVILLE, TN · NPI 1083669345
Verified facts
What the public records show
CMS Open Payments records show Douglas L Davis, M.D. received $424.29 in general payments during 2025 across 24 reported records.
Novartis Pharmaceuticals Corporation accounted for 26.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $113.48 | 26.8% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $50.66 | 11.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $50.59 | 11.9% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.46 | 8.1% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $30.52 | 7.2% | 2 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $28.92 | 6.8% | 1 | 2025 |
| Soleno Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.70 | 5.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.38 | 5.0% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $19.88 | 4.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.85 | 4.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.64 | 3.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.21 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $405.44 | 23 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $113.48 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $37.18 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $34.46 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $32.22 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $30.52 | 2 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $28.92 | 1 | 2025 |
Source payment records
|
|||||
| VYKAT XR Normalized: vykat xr |
Drug | Soleno Therapeutics, Inc. | $23.70 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.38 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $21.38 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $19.88 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 47 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 115 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
115 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 656 | 168 |
| Levothyroxine Sodium | Levothyroxine Sodium | 543 | 131 |
| Amlodipine Besylate | Amlodipine Besylate | 458 | 108 |
| Ezetimibe | Ezetimibe | 406 | 110 |
| Atorvastatin Calcium | Atorvastatin Calcium | 386 | 101 |
| Losartan Potassium | Losartan Potassium | 368 | 96 |
| Zolpidem Tartrate | Zolpidem Tartrate | 304 | 65 |
| Omeprazole | Omeprazole | 263 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 216 | 57 |
| Metformin Hcl Er | Metformin Hcl | 196 | 49 |
| Gabapentin | Gabapentin | 175 | 43 |
| Sertraline Hcl | Sertraline Hcl | 163 | 45 |
| Montelukast Sodium | Montelukast Sodium | 162 | 38 |
| Famotidine | Famotidine | 155 | 42 |
| Pioglitazone Hcl | Pioglitazone Hcl | 145 | 37 |
| Potassium Chloride | Potassium Chloride | 145 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 143 | 35 |
| Meloxicam | Meloxicam | 139 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 127 | 27 |
| Glimepiride | Glimepiride | 125 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 124 | 34 |
| Lisinopril | Lisinopril | 121 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 121 | 34 |
| Alprazolam | Alprazolam | 119 | 22 |
| Azithromycin | Azithromycin | 119 | 80 |
| Duloxetine Hcl | Duloxetine Hcl | 117 | 24 |
| Ozempic | Semaglutide | 115 | 20 |
| Mounjaro | Tirzepatide | 114 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 111 | 64 |
| Methylprednisolone | Methylprednisolone | 105 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 100 | 35 |
| Allopurinol | Allopurinol | 96 | 24 |
| Eliquis | Apixaban | 95 | 21 |
| Xarelto | Rivaroxaban | 88 | 14 |
| Simvastatin | Simvastatin | 84 | 24 |
| Lorazepam | Lorazepam | 83 | 16 |
| Baclofen | Baclofen | 79 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 79 | 21 |
| Tramadol Hcl | Tramadol Hcl | 77 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 75 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 19 |
| Mirtazapine | Mirtazapine | 74 | 14 |
| Pregabalin | Pregabalin | 74 | 13 |
| Ramipril | Ramipril | 73 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 72 | 24 |
| Carvedilol | Carvedilol | 72 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 70 | 18 |
| Cephalexin | Cephalexin | 68 | 55 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 68 | 22 |
| Spironolactone | Spironolactone | 68 | 11 |
| Benazepril Hcl | Benazepril Hcl | 62 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 21 |
| Trazodone Hcl | Trazodone Hcl | 59 | 14 |
| Metformin Hcl | Metformin Hcl | 56 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 13 |
| Repatha Sureclick | Evolocumab | 56 | suppressed |
| Furosemide | Furosemide | 53 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 53 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 13 |
| Guanfacine Hcl | Guanfacine Hcl | 47 | 11 |
| Jardiance | Empagliflozin | 47 | 12 |
| Synthroid | Levothyroxine Sodium | 47 | 14 |
| Bupropion Xl | Bupropion Hcl | 45 | 13 |
| Buspirone Hcl | Buspirone Hcl | 45 | 12 |
| Clonazepam | Clonazepam | 44 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 44 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | 13 |
| Levetiracetam | Levetiracetam | 43 | suppressed |
| Atenolol | Atenolol | 42 | suppressed |
| Irbesartan | Irbesartan | 42 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 41 | 13 |
| Donepezil Hcl | Donepezil Hcl | 41 | suppressed |
| Finasteride | Finasteride | 40 | suppressed |
| Myrbetriq | Mirabegron | 40 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | suppressed |
| Nystatin | Nystatin | 37 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 29 |
| Fluconazole | Fluconazole | 35 | 18 |
| Amoxicillin | Amoxicillin | 32 | 24 |
| Celecoxib | Celecoxib | 32 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 31 | 15 |
| Guanfacine Hcl Er | Guanfacine Hcl | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 28 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Bumetanide | Bumetanide | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Niacin Er | Niacin | 25 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Klor-Con M20 | Potassium Chloride | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | 12 |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Repatha Syringe | Evolocumab | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Nadolol | Nadolol | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 12 |
| Acyclovir | Acyclovir | 15 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Prednisone | Prednisone | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 13 | 13 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Tobramycin | Tobramycin | 12 | suppressed |
| Zolmitriptan | Zolmitriptan | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Etodolac | Etodolac | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Theo-24 | Theophylline Anhydrous | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $424.29 · 24 records | Novartis Pharmaceuticals Corporation | AIRSUPRA, AREXVY, CAPLYTA, FARXIGA, GVOKE HYPOPEN, JARDIANCE, LEQVIO, NEXLETOL, OTEZLA, Ozempic, REPATHA, Rybelsus, SHINGRIX, TONMYA, TZIELD, VYKAT XR, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error